Related Experiment Video
Updated: Jun 27, 2025
Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds
Published on: September 8, 2021
Discovery of N,N'-diarylurea molecules with activity against multidrug-resistant Staphylococcus aureus
Hui-Hui Yeo1, Yu-Hsuan Jao2, Fan-Wei Yang3
1Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Abstract:
The emergence and global spread of methicillin-resistant Staphylococcus aureus (MRSA) pose a serious threat to public health, underscoring the urgent need for novel antibacterial interventions. Here, we screened 18 newly synthesized N,N'-diarylurea derivatives to identify compounds with activity against MRSA. Our investigations led to the discovery of a small molecule, SCB-24, which exhibited promising antimicrobial activity against MRSA USA300. Notably, SCB-24 demonstrated high activity even in the presence of 10% fetal bovine serum and showed excellent selectivity for bacterial over mammalian cells. SCB-24 also showed potent activity against various MRSA strains, including those resistant to second- and third-line antibiotics. Importantly, the efficacy of SCB-24 was inferior to that of vancomycin in MRSA-infected Galleria mellonella larvae. Overall, our findings suggest that SCB-24 has great potential as a new therapeutic for multidrug-resistant S. aureus infections.
Insights
A new compound, SCB-24, shows promise in fighting methicillin-resistant Staphylococcus aureus (MRSA) infections. This novel N,N-diarylurea derivative is effective against multidrug-resistant MRSA strains and selective for bacterial cells.
Area of Science:
- Medicinal Chemistry
- Microbiology
- Infectious Diseases
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) presents a significant global health challenge.
- There is a critical need for new antibacterial agents to combat rising antimicrobial resistance.
Purpose of the Study:
- To screen novel N,N'-diarylurea derivatives for activity against MRSA.
- To identify and characterize promising lead compounds for the treatment of MRSA infections.
Main Methods:
- Synthesis and screening of 18 N,N'-diarylurea derivatives against MRSA USA300.
- Evaluation of compound activity in the presence of fetal bovine serum.
- Assessment of selectivity against mammalian cells.
- Testing against diverse MRSA strains, including those with resistance to existing antibiotics.
- In vivo efficacy testing using Galleria mellonella infection model.
Main Results:
- SCB-24, a novel N,N'-diarylurea derivative, demonstrated significant antimicrobial activity against MRSA USA300.
- SCB-24 maintained high activity in 10% fetal bovine serum and exhibited excellent bacterial selectivity.
- The compound was potent against multiple MRSA strains, including those resistant to second- and third-line antibiotics.
- In vivo, SCB-24's efficacy was less than vancomycin in a Galleria mellonella model.
Conclusions:
- SCB-24 exhibits potent in vitro activity against multidrug-resistant MRSA.
- Its selectivity and activity in serum suggest therapeutic potential.
- Further development is warranted to explore SCB-24 as a novel agent for treating S. aureus infections.
Related Concept Videos
01:11Aryldiazonium Salts to Azo Dyes: Diazo Coupling
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:07Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview